Holen Sie sich die Stockscreener-App
4.35
0.62%
-0.02
Schlusskurs vom Vortag:
$4.37
Offen:
$4.38
24-Stunden-Volumen:
289.18K
Relative Volume:
0.47
Marktkapitalisierung:
$299.15M
Einnahmen:
$113.02M
Nettoeinkommen (Verlust:
$-75.07M
KGV:
-4.1719
EPS:
-1.0427
Netto-Cashflow:
$-47.88M
1W Leistung:
-2.63%
1M Leistung:
+7.50%
6M Leistung:
+73.02%
1J Leistung:
+42.39%
1-Tages-Spanne:
$4.21
$4.40
1-Wochen-Bereich:
$4.21
$4.51
52-Wochen-Spanne:
$2.08
$4.58
Orasure Technologies Inc Stock (OSUR) Company Profile
Firmenname
Orasure Technologies Inc
Sektor
Telefon
(503) 641-6115
Adresse
220 E FIRST ST, BETHLEHEM, PA
Compare OSUR vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OSUR
Orasure Technologies Inc
|
4.345 | 299.49M | 113.02M | -75.07M | -47.88M | -1.0427 |
ISRG
Intuitive Surgical Inc
|
426.49 | 150.88B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.46 | 43.56B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.81 | 36.52B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.22 | 33.97B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
219.34 | 30.41B | 5.54B | 1.52B | 1.74B | 10.37 |
Orasure Technologies Inc Stock (OSUR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-03 | Fortgesetzt | Evercore ISI | In-line |
| 2021-09-22 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-08-21 | Eingeleitet | Evercore ISI | Outperform |
| 2020-08-10 | Eingeleitet | Citigroup | Buy |
| 2020-08-10 | Eingeleitet | JP Morgan | Neutral |
| 2020-08-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-06-25 | Eingeleitet | Lake Street | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Equal-Weight |
| 2018-10-23 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-07-16 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2017-11-02 | Herabstufung | Jefferies | Buy → Hold |
| 2017-02-09 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2016-06-13 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2015-11-05 | Bestätigt | Mizuho | Buy |
| 2015-05-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-01-23 | Bestätigt | Mizuho | Buy |
| 2014-06-12 | Bestätigt | Canaccord Genuity | Buy |
| 2014-06-11 | Bestätigt | Mizuho | Buy |
| 2012-12-21 | Eingeleitet | Mizuho | Buy |
| 2012-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2012-07-05 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2012-03-27 | Eingeleitet | JMP Securities | Mkt Outperform |
Alle ansehen
Orasure Technologies Inc Aktie (OSUR) Neueste Nachrichten
OraSure Technologies updates highlight diagnostics focus amid shifting health trends - AD HOC NEWS
OSUROrasure Technologies Inc Latest SEC Filings - Finviz
Form 4 OraSure Technologies Inc For: 30 June By Investing.com - Investing.com Nigeria
OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash - Stock Titan
Enterprise value to EBIT forward of OraSure Technologies, Inc. – MUN:EP3 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to book forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to sales forward of OraSure Technologies, Inc. – NASDAQ:OSUR - TradingView
Price to sales forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to revenue forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Price to earnings forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
Enterprise value to EBITDA forward of OraSure Technologies, Inc. – LSX:881351 - TradingView
OraSure gets FDA nod for at-home STI urine collection kit - Investing.com Nigeria
3 Promising Penny Stocks With At Least $200M Market Cap - simplywall.st
OraSure Technologies (OSUR) Pressured: Testing Support After Recent DeclineDay Trade Opportunities - dars.gov.et
OraSure Technologies Hits New 52-Week High of $4.36, Marking Significant Growth - MarketsMojo
OraSure Technologies Inc (OSUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OraSure Technologies Inc (OSUR) Institutional Confidence - TradingKey
OraSure Technologies Inc (OSUR) Valuation: PE, PB & Fair Value Analysis - TradingKey
OraSure Technologies Inc (OSUR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OraSure Technologies Inc (OSUR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OraSure Technologies Inc (OSUR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OraSure Technologies Inc (OSUR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OraSure Technologies Inc (OSUR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OraSure Wins FDA Clearance for At-Home STI Collection - The Globe and Mail
OraSure receives FDA clearance for home urine collection kit for STIs - Lehigh Valley Business
Is Taysha Gene Therapies, Inc. (TSHA) A Good Stock To Buy Now? - Yahoo Finance
FDA Clears Home Urine Collection Kit for STI Testing - Conexiant
OraSure secures FDA clearance for product seen as key to future growth - WFMZ.com
OraSure stock jumps on FDA clearance for at-home STI kit - Investing.com
OraSure stock jumps on FDA clearance for at-home STI kit By Investing.com - Investing.com South Africa
OraSure Technologies (NASDAQ: OSUR) wins FDA clearance for Colli-Pee Dx at-home urine collection kit - Stock Titan
OraSure gets FDA nod for at-home STI urine collection kit By Investing.com - Investing.com Australia
OraSure receives FDA clearance for at-home STI urine collection kit - StreetInsider
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections - The Manila Times
OraSure Technologies, Inc. Announces FDA Clearance that - GlobeNewswire
OraSure Technologies (OSUR) Slips 3.1% as Stock Tests Key Support LevelOvernight Profile - newsline.com
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Yahoo Finance
OraSure Technologies (OSUR) director receives 46,106-share restricted stock grant - Stock Titan
OraSure (OSUR) director Nancy Gagliano receives 46,106-share stock award - Stock Titan
OraSure Technologies (OSUR) director receives 46,106-share stock grant - Stock Titan
OraSure (OSUR) director John P. Kenny granted 46,106 restricted shares - Stock Titan
Director at OraSure (NASDAQ: OSUR) receives 46,106 restricted shares - Stock Titan
OraSure Shares Jump as Board Reset Draws Investor Focus - Bez Kabli
Earnings call transcript: OraSure Technologies Q1 2026 misses earnings and revenue forecasts - Investing.com UK
OraSure Technologies Investors Approve Expanded Stock Plan, Governance Changes - The Globe and Mail
OraSure Technologies (NASDAQ: OSUR) OKs more equity awards and board declassification - Stock Titan
OraSure Technologies Hits New 52-Week High of $4.33, Marking Significant Growth - Markets Mojo
OSUR Q1 2026 Earnings: EPS Miss by 69% Signals Operational HeadwindsFree Cash Flow Trends - newsline.com
Finanzdaten der Orasure Technologies Inc-Aktie (OSUR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Orasure Technologies Inc-Aktie (OSUR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Boyd Steven Kyle | Director |
May 14 '26 |
Buy |
2.99 |
25,000 |
74,750 |
113,462 |
| Boyd Steven Kyle | Director |
May 12 '26 |
Buy |
2.98 |
25,000 |
74,500 |
63,462 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,600 |
589,562 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 20 '26 |
Buy |
2.93 |
32,300 |
94,597 |
2,190,874 |
| McGrath Kenneth J | Chief Financial Officer |
Mar 13 '26 |
Buy |
3.00 |
22,021 |
66,030 |
557,262 |
| EGLINTON MANNER CARRIE | President & CEO |
Mar 13 '26 |
Buy |
3.00 |
22,022 |
66,033 |
2,158,574 |
2.23%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):